Safety and Efficacy of Topical NVC-422 Gel in Impetigo

NovaBay Pharmaceuticals, Inc.129 enrolled

Overview

This is a randomized, double-blind study comparing 0.1% NVC-422, 0.5% NVC-422 and 1.5% NVC-422 topical gel in children with impetigo.

This study is a randomized, sequential group, double-blind study. The first 60 subjects enrolled will be randomized to either 0.1% NVC-422 or 0.5% NVC-422. Randomization is 1:2 where 20 subjects will receive 0.1% NVC-422 and 40 subjects will receive 0.5% NVC-422. If there are no safety issues regarding the first 2 doses tested, the next 60 subjects will be randomized to either 0.1% or 1.5% NVC-422 with 20 subjects receiving 0.1% and 40 subjects receiving 1.5% NVC-422. The lesion most representative of the subject's infection will be identified as the target lesion. This target lesion will be photographed, graded clinically, and its location recorded. At Visit 1, Screening and/or Baseline, a Gram stain will be performed to assess presence of Gram-positive cocci. If Gram-positive cocci are present, a swab for culture and sensitivity will be obtained. Treatment will began immediately after randomization. Treatment will be 3 times per day (TID) for 7 consecutive days, following a morning, afternoon, and evening schedule. After the start of treatment (Day 1), subjects will be assessed for safety on Day 4 (± 1). Clinical and bacteriological assessments of the target lesion will also occur on Day 8 (+1) and Follow-up on Day 15 (± 2).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

129

Conditions

Impetigo

Interventions

NVC-422DRUG

Dermal Gel applied 3 times per day for 7 days

Eligibility

Sex: ALLMin age: 2 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects must be 2 - 12 years of age * Parents or Legal Guardians must sign a written informed consent document * Positive Gram stain of target lesion showing Gram-positive cocci; * Clinical diagnosis of primary non-bullous impetigo as per the protocol * Skin Infection Rating Scale total score of at least 4, with at least three of the five primary signs and symptoms present at baseline including a score of 1 or greater for exudate/pus; * Screening within one day of enrollment into the study. Exclusion Criteria: * Presence of other skin diseases at or near the investigational target area to be treated; * Disease is so widespread or severe that, in the opinion of the investigator, oral antibiotic treatment is needed * Active impetigo lesions greater than 5 cm2 * Signs and symptoms of a current infection requiring antibiotic treatment * Use of systemic or topical antibiotics or steroids within 72 hours prior to study entry * Females of childbearing potential

Locations (2)

Hospital Infantil Dr. Robert Reid Cabral

Santo Domingo, Dominican Republic

Instituto Dermatológico

Santo Domingo, Dominican Republic

Outcomes

Primary Outcomes

Clinical Response

Sufficient resolution of signs and symptoms of infection of the target lesion such that no additional antimicrobial therapy is required to treat the impetigo as evidenced by the SIRS score of 0 each for exudate/pus, crusting and pain and 0 or 1 each for erythema/inflammation and itching for a clinical success or a SIRS score of 0 for exudate/pus but does not meet all the criteria for clinical success for a clinical improvement.

Time frame: End of Treatment (Day 8) and Follow-up (Day 15)

Secondary Outcomes

Bacteriological Response

The causative pathogen isolated from the target lesion at Baseline (Staphylococcus aureus and/or Streptococcus pyogenes) are eliminated on culture, or response is such that no material was available for culture and therefore is evidence of pathogen eradication.

Time frame: End of Treatment (Day 8) and Follow-up (Day 15)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.